HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Takuya Tsunoda Selected Research

Pancreatic Neoplasms (Pancreatic Cancer)

1/2024Precise Non-invasive Imaging Mouse Model of Pancreatic Cancer: Very Narrow Band-width Laser Fluorescence Excitation of Green Fluorescent Protein Provides Ultra-bright Tumor Images With no Skin Autofluorescence.
5/2022Stage IV Pancreatic Cancer Patient Treated With FOLFIRINOX Combined With Oral Methioninase: A Highly-Rare Case With Long-term Stable Disease.
1/2021High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor prognosis in pancreatic cancer.
1/2020High expression levels of polymeric immunoglobulin receptor are correlated with chemoresistance and poor prognosis in pancreatic cancer.
1/2020High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer.
7/2015Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study.
2/2010Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer.
11/2008[A phase I study of combination-therapy with gemcitabine and epitope peptides derived from human vascular endothelial growth factor receptor for unresectable or recurrent pancreas cancer].
10/2008Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Takuya Tsunoda Research Topics

Disease

78Neoplasms (Cancer)
05/2024 - 03/2002
17Colorectal Neoplasms (Colorectal Cancer)
11/2023 - 03/2002
9Pancreatic Neoplasms (Pancreatic Cancer)
01/2024 - 10/2008
9Testicular Neoplasms (Testicular Cancer)
01/2018 - 08/2005
8Neoplasm Metastasis (Metastasis)
01/2024 - 06/2002
8Stomach Neoplasms (Stomach Cancer)
12/2021 - 03/2002
7Colonic Neoplasms (Colon Cancer)
01/2024 - 12/2004
6Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2023 - 02/2021
6Urinary Bladder Neoplasms (Bladder Cancer)
01/2022 - 12/2008
5Esophageal Neoplasms (Esophageal Cancer)
01/2024 - 11/2007
5Lung Neoplasms (Lung Cancer)
01/2018 - 03/2002
4Carcinoma (Carcinomatosis)
05/2024 - 07/2004
4Esophageal Squamous Cell Carcinoma
04/2014 - 07/2008
2Lobular Carcinoma
01/2024 - 12/2022
2Breast Neoplasms (Breast Cancer)
01/2024 - 12/2022
2Hepatocellular Carcinoma (Hepatoma)
11/2023 - 08/2005
2Rectal Neoplasms (Rectal Cancer)
09/2023 - 08/2022
2Obesity
01/2023 - 07/2022
2Diarrhea
11/2022 - 03/2022
2Disease Progression
08/2022 - 12/2021
2Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
07/2022 - 01/2005
2Residual Neoplasm
02/2022 - 04/2014
2Melanoma (Melanoma, Malignant)
02/2021 - 03/2002
2Renal Cell Carcinoma (Grawitz Tumor)
01/2014 - 12/2008
1Alopecia (Baldness)
05/2024
1Glioma (Gliomas)
12/2023
1Triple Negative Breast Neoplasms
11/2023
1Glioblastoma (Glioblastoma Multiforme)
01/2023
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2023

Drug/Important Bio-Agent (IBA)

30Peptides (Polypeptides)IBA
11/2023 - 07/2003
21EpitopesIBA
05/2018 - 07/2003
21AntigensIBA
01/2018 - 07/2003
14Immune Checkpoint InhibitorsIBA
01/2024 - 09/2019
12Methionine (L-Methionine)FDA Link
05/2024 - 08/2022
12Complementary DNA (cDNA)IBA
06/2016 - 07/2003
11L-methionine gamma-lyaseIBA
05/2024 - 05/2022
11Messenger RNA (mRNA)IBA
02/2022 - 03/2002
9Biomarkers (Surrogate Marker)IBA
05/2024 - 03/2021
9Cancer VaccinesIBA
01/2016 - 07/2003
8Protein Subunit VaccinesIBA
11/2023 - 11/2008
7Proteins (Proteins, Gene)FDA Link
01/2021 - 12/2004
6Carrier Proteins (Binding Protein)IBA
06/2016 - 07/2003
6Insulin-Like Growth Factor II (Somatomedin A)IBA
06/2016 - 11/2007
5Protein Kinases (Protein Kinase)IBA
04/2014 - 11/2007
5HLA-A*02:01 antigenIBA
10/2006 - 12/2004
4HLA-A Antigens (HLA-A)IBA
05/2018 - 12/2004
4VaccinesIBA
05/2018 - 12/2012
4Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
07/2015 - 06/2005
4Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA
04/2014 - 10/2006
4HLA-A24 AntigenIBA
04/2011 - 07/2004
3regorafenibIBA
11/2023 - 01/2020
3pembrolizumabIBA
09/2023 - 01/2022
3NivolumabIBA
09/2023 - 05/2021
3B7-H1 AntigenIBA
01/2023 - 02/2021
3Carcinoembryonic AntigenIBA
12/2022 - 07/2003
3Irinotecan (Camptosar)FDA LinkGeneric
05/2022 - 01/2021
3EnzymesIBA
12/2021 - 08/2009
3GemcitabineFDA Link
07/2015 - 11/2008
3HLA-A2 Antigen (HLA A2 Antigen)IBA
01/2014 - 10/2008
3Cadherins (E-Cadherin)IBA
08/2012 - 10/2008
3Insulin-Like PeptidesIBA
08/2009 - 11/2007
2HomocysteineIBA
05/2024 - 05/2023
2Glucose (Dextrose)FDA LinkGeneric
01/2024 - 01/2023
2Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
11/2023 - 11/2008
2Bevacizumab (Avastin)FDA Link
09/2023 - 01/2019
2LigandsIBA
09/2023 - 01/2023
2AntibodiesIBA
09/2023 - 12/2021
2Fluorouracil (Carac)FDA LinkGeneric
01/2023 - 05/2022
2Cisplatin (Platino)FDA LinkGeneric
01/2023 - 10/2012
2Therapeutic UsesIBA
12/2022 - 02/2022
2Cyclophosphamide (Cytoxan)FDA LinkGeneric
12/2022 - 01/2016
2Alanine Transaminase (SGPT)IBA
11/2022 - 06/2021
2Aspartate Aminotransferases (Aspartate Transaminase)IBA
11/2022 - 06/2021
2Imatinib Mesylate (Gleevec)FDA Link
07/2022 - 01/2005
2Oxaliplatin (Eloxatin)FDA LinkGeneric
01/2020 - 01/2019
2Capecitabine (Xeloda)FDA Link
01/2020 - 01/2019
2arginyl- phenylalanyl- valyl- prolyl- aspartyl- glycyl- asparagyl- arginyl- isoleucineIBA
07/2015 - 12/2012
2T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA
01/2014 - 08/2013
2KinesinsIBA
08/2013 - 01/2012
2Small Interfering RNA (siRNA)IBA
08/2006 - 08/2005
1Volatile Fatty AcidsIBA
05/2024
1isobutyric acidIBA
05/2024
1Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
01/2024
1Red Fluorescent ProteinIBA
01/2024
1Green Fluorescent ProteinsIBA
01/2024
1MethyltransferasesIBA
12/2023
1Temozolomide (Temodar)FDA LinkGeneric
12/2023
1Phosphates (Orthophosphate)IBA
11/2023
1Cytotoxins (Cytolysins)IBA
05/2023
1IsotopesIBA
01/2023
1Deoxyglucose (2 Deoxy D glucose)IBA
01/2023

Therapy/Procedure

27Therapeutics
05/2024 - 03/2002
25Immunotherapy
05/2024 - 07/2003
12Drug Therapy (Chemotherapy)
01/2024 - 02/2005
3Lasers (Laser)
01/2024 - 03/2021
3Aftercare (After-Treatment)
01/2024 - 09/2019
2Oral Administration
05/2024 - 01/2023
2Radiotherapy
09/2023 - 07/2012
1Combination Drug Therapy (Combination Chemotherapy)
01/2024
1Laparotomy
01/2024